Boothbay Fund Management, LLC Cardiff Oncology, Inc. Transaction History
Boothbay Fund Management, LLC
- $3.27 Billion
- Q4 2024
A detailed history of Boothbay Fund Management, LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Boothbay Fund Management, LLC holds 129,960 shares of CRDF stock, worth $593,917. This represents 0.02% of its overall portfolio holdings.
Number of Shares
129,960Holding current value
$593,917% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding CRDF
# of Institutions
124Shares Held
25.2MCall Options Held
866KPut Options Held
203K-
Commodore Capital LP New York, NY5.38MShares$24.6 Million2.34% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$12 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.28MShares$10.4 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA1.54MShares$7.03 Million0.18% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.44MShares$6.59 Million3.38% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $198M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...